ElevateBio launches HighPassBio with TCR immunotherapy focus

Less than five months after its launch, ElevateBio has announced a second portfolio company: HighPassBio, which is developing T cell immunotherapies based on research from the Fred Hutchinson Cancer Research Center.

HighPassBio’s lead candidate is a T cell receptor therapy intended to treat and prevent relapse after hematopoietic stem cell transplant (HSCT) in leukemia patients that was developed in the lab of Marie Bleakley, the company’s scientific founder...